Iopamidol

The dosage of Iopamidol is highly individualized and is determined by the radiologist or attending physician based on the specific diagnostic procedure, the patient's body weight, and the vascular area being imaged.

• Cerebral Angiography: For visualizing the blood vessels in the brain, the typical dose ranges from 8 to 12 mL of a 300 mgI/mL solution per injection. Multiple injections may be required, but the total dose usually does not exceed 90 mL.
• Peripheral Arteriography: For imaging the legs or arms, doses typically range from 10 to 50 mL, depending on the specific artery being studied.
• Contrast-Enhanced CT (Body Imaging): For a standard CT scan of the chest, abdomen, or pelvis, the usual dose is 100 to 150 mL of a 300 mgI/mL solution, often administered via an automated power injector.
• Excretory Urography: To evaluate the kidneys, a dose of 25 to 50 mL of a 370 mgI/mL solution is common.

Iopamidol is approved for use in pediatric patients, including infants. Dosing in children is strictly based on body weight to ensure safety.

• General Pediatric Dosing: The typical dose for many procedures is 1.0 mL to 3.0 mL per kilogram (kg) of body weight.
• Maximum Limits: The total dose in children should generally not exceed 3.0 mL/kg or a total of 100 mL, whichever is lower, unless specifically directed by a pediatric radiologist.
• Neonates: In newborns, healthcare providers exercise extreme caution due to the immature state of the infant's kidneys and the potential for shifts in fluid balance.

Renal Impairment

Patients with pre-existing kidney disease are at a higher risk for Contrast-Induced Nephropathy (CIN), a sudden decline in kidney function following contrast administration. For these patients, healthcare providers may use the lowest effective dose of Iopamidol and ensure the patient is aggressively hydrated with intravenous fluids before and after the procedure. In cases of severe renal failure, the procedure may be postponed or an alternative imaging method (like ultrasound or non-contrast MRI) may be chosen.

Hepatic Impairment

Since Iopamidol is excreted almost exclusively by the kidneys, dosage adjustments are generally not required for patients with liver disease. However, the patient's overall clinical status must be considered.

Elderly Patients

Older adults are more likely to have reduced renal function and underlying cardiovascular disease. Healthcare providers typically assess creatinine clearance (a measure of kidney health) in elderly patients before administering Iopamidol. Dosing is often conservative, starting at the lower end of the range.

Iopamidol is not a medication you take yourself at home. It is administered exclusively by trained medical professionals in a hospital or imaging center setting.

• Preparation: You may be asked to fast (not eat) for several hours before the procedure to reduce the risk of nausea or complications if an allergic reaction occurs.
• Hydration: It is vital to drink plenty of water before and after the procedure (unless instructed otherwise for medical reasons) to help your kidneys flush the contrast agent out of your system.
• Administration: The agent is usually injected through an intravenous (IV) line. You may feel a brief sensation of warmth or a metallic taste in your mouth during the injection; this is normal.
• Storage: In the clinical setting, Iopamidol is stored at room temperature (20°C to 25°C) and protected from light. It should not be used if the solution is discolored or contains particulate matter.

Because Iopamidol is administered as a single dose for a specific diagnostic event, there is no "missed dose" in the traditional sense. If a scheduled imaging procedure is missed, it must be rescheduled with the imaging facility.

An overdose of Iopamidol is rare because it is administered by professionals using controlled volumes. However, if an excessive amount is given, it can lead to severe strain on the kidneys and cardiovascular system. Symptoms of overdose may include difficulty breathing, extreme fatigue, or signs of kidney failure (reduced urination). In the event of a significant overdose, especially in patients with poor kidney function, hemodialysis (blood filtering) may be used to rapidly remove the contrast agent from the body.

> Important: Follow your healthcare provider's dosing instructions and pre-procedure guidelines exactly. Do not adjust your fluid intake or fast without medical guidance.

Most patients tolerate Iopamidol well, but because it is a foreign substance injected into the vascular system, some physiological responses are common. These usually occur during or immediately after the injection and are typically short-lived:

• Sensation of Warmth or Flushing: Many patients report a "hot flash" feeling that travels through the body. This is caused by the contrast agent temporarily dilating blood vessels.
• Metallic Taste: A brief, strange taste in the mouth is frequently reported.
• Nausea: A mild feeling of stomach upset may occur, which is why fasting is often recommended before the scan.
• Injection Site Reactions: Mild pain, coldness, or bruising at the site where the IV was inserted.

These side effects may require monitoring but are generally not life-threatening:

• Vomiting: More intense than simple nausea, this usually resolves quickly.
• Hives (Urticaria): Small, itchy red bumps on the skin. This is a mild allergic-like reaction.
• Headache: Some patients experience a mild to moderate headache following the procedure.
• Dizziness: A brief feeling of lightheadedness or spinning.
• Chills or Fever: A temporary disruption in temperature regulation.

Rare but more significant reactions include:

• Delayed Skin Rashes: Rashes that appear 2 to 7 days after the procedure.
• Hypotension (Low Blood Pressure): A sudden drop in blood pressure that may cause fainting.
• Tachycardia: An abnormally fast heart rate.
• Bronchospasm: Tightening of the airways, making it difficult to breathe (more common in patients with asthma).

In rare instances, Iopamidol can cause life-threatening reactions. Medical staff are trained to monitor for these during the procedure.

> Warning: Stop the procedure (if still in progress) and call for emergency help immediately if you experience any of the following after leaving the clinic:

• Anaphylaxis: A severe allergic reaction characterized by swelling of the face, lips, or throat, extreme difficulty breathing, and a rapid drop in blood pressure.
• Contrast-Induced Nephropathy (CIN): Sudden kidney damage. Symptoms include a significant decrease in urination, swelling in the legs or ankles, and unusual fatigue.
• Seizures: Iopamidol can lower the seizure threshold, particularly if it enters the central nervous system.
• Thyroid Storm: In patients with hyperthyroidism, the iodine in Iopamidol can trigger a dangerous surge in thyroid hormones, leading to high fever, rapid heart rate, and confusion.
• Cardiac Arrest or Arrhythmia: Severe disturbances in heart rhythm, especially during cardiac catheterization procedures.
• Extravasation Necrosis: If the contrast leaks out of the vein into the surrounding tissue (extravasation), it can cause severe tissue damage or skin death (necrosis).

Iopamidol is generally cleared from the body within 24 hours, so long-term side effects are extremely rare. However, two specific concerns exist:

1. 1Thyroid Function: In infants and patients with existing thyroid disease, the large bolus of iodine can affect thyroid hormone levels for several weeks after the procedure. Follow-up testing may be required.
2. 2Nephrogenic Systemic Fibrosis (NSF): While primarily associated with Gadolinium (used in MRI), there have been historical discussions about contrast agents and skin thickening; however, Iopamidol is not known to cause NSF. The primary long-term risk remains potential permanent kidney damage if a severe case of CIN is not managed correctly.

No FDA black box warnings currently exist for Iopamidol. However, there are "Special Warnings" regarding its use in myelography (spinal imaging). If used intrathecally (into the spine), extreme care must be taken to avoid overdose, which can cause fatal seizures or cerebral edema.

Report any unusual symptoms, especially those occurring days after your scan, to your healthcare provider immediately.

Iopamidol is a diagnostic tool that must be used with caution, particularly in patients with a history of allergies or certain chronic health conditions. Before receiving Iopamidol, it is essential to disclose your full medical history to your radiologist. The most significant risks involve allergic-type reactions and potential damage to the kidneys. Patients who have had a previous reaction to any iodinated contrast media are at a five-fold increased risk of having another reaction.

As of 2024, there are no FDA black box warnings for Iopamidol. It is considered one of the safer non-ionic contrast agents available. However, the absence of a black box warning does not mean the drug is without risk; severe and fatal reactions have occurred, necessitating administration only in settings equipped for emergency resuscitation.

• Allergic Reactions / Anaphylaxis Risk: Severe, life-threatening allergic reactions (anaphylactoid reactions) can occur even in patients with no prior exposure to Iopamidol. These reactions are unpredictable. Patients with asthma, hay fever, or food allergies (especially shellfish, though the "shellfish-iodine" link is a common myth) may be at a slightly higher risk.
• Nephrotoxicity (Kidney Toxicity): Iopamidol can cause a temporary or permanent decrease in kidney function. This risk is highest in patients with pre-existing renal insufficiency, diabetes mellitus, dehydration, or those taking other medications that stress the kidneys.
• Cardiovascular Stress: The injection of contrast can cause temporary changes in blood pressure and heart rate. Patients with congestive heart failure or severe coronary artery disease must be monitored closely, as the fluid shift caused by the contrast can exacerbate heart failure.
• Thyroid Disorders: Because Iopamidol contains iodine, it can trigger a "thyroid storm" in patients with hyperthyroidism (an overactive thyroid) or cause hypothyroidism in newborns.
• Pheochromocytoma: In patients with this rare tumor of the adrenal gland, contrast agents can trigger a dangerous spike in blood pressure (hypertensive crisis).
• Sickle Cell Disease: Contrast media can promote the "sickling" of red blood cells in patients who are homozygous for sickle cell disease.

Healthcare providers will typically perform the following before and after Iopamidol administration:

• Serum Creatinine/eGFR: To assess kidney function before the procedure.
• Vital Signs: Monitoring blood pressure, heart rate, and oxygen levels during and for at least 30-60 minutes after the injection.
• Hydration Status: Ensuring the patient is well-hydrated to protect the kidneys.
• Thyroid Screening: In neonates, thyroid function should be checked within 7-10 days following exposure to iodinated contrast.

Iopamidol itself does not usually cause impairment. However, the diagnostic procedure (such as angiography) or any sedative medications given alongside the contrast may make you drowsy or dizzy. It is generally advised not to drive or operate heavy machinery for at least 24 hours if you received sedation or if you feel unwell after the procedure.

There is no direct chemical interaction between Iopamidol and alcohol. However, alcohol is a diuretic and can lead to dehydration. Since dehydration significantly increases the risk of kidney damage from Iopamidol, patients should avoid alcohol for at least 24 hours before and after the procedure.

As Iopamidol is a single-use diagnostic agent, there is no tapering or withdrawal syndrome. The focus after administration is on ensuring the drug is fully eliminated from the body through adequate fluid intake.

> Important: Discuss all your medical conditions, especially kidney disease, heart disease, and thyroid issues, with your healthcare provider before starting Iopamidol.

While there are no drugs that are strictly "contraindicated" in a way that prevents the use of Iopamidol in an emergency, certain combinations are avoided in elective settings:

• Metformin: While not a direct interaction, if Iopamidol causes sudden kidney failure, Metformin can accumulate in the body and cause a life-threatening condition called lactic acidosis. Most guidelines recommend stopping Metformin at the time of the procedure and withholding it for 48 hours afterward, resuming only after kidney function is confirmed to be normal.

• Nephrotoxic Drugs: Medications that can damage the kidneys should be avoided or used with extreme caution near the time of Iopamidol administration. This includes:
• NSAIDs (e.g., Ibuprofen, Naproxen)
• Aminoglycoside Antibiotics (e.g., Gentamicin)
• Platinum-based Chemotherapy (e.g., Cisplatin)
• Certain Antivirals (e.g., Acyclovir)
• Interleukin-2 (IL-2): Patients who have recently received IL-2 therapy for cancer have a significantly higher risk of "recall" reactions, where they experience flu-like symptoms or skin rashes several hours after receiving Iopamidol.

• Beta-Blockers (e.g., Metoprolol, Atenolol): These drugs can make allergic reactions more difficult to treat because they may reduce the effectiveness of epinephrine (adrenaline), which is used to treat anaphylaxis.
• Vasoactive Drugs: Medications that affect blood pressure (like ACE inhibitors or diuretics) may increase the risk of a sudden drop in blood pressure or kidney stress during the procedure.

• Dehydration: The most critical "interaction" is with your hydration status. High-protein meals or excessive caffeine (which acts as a diuretic) should be avoided on the day of the procedure to ensure your kidneys are well-protected.
• Dairy: There is no specific interaction with dairy, though a light meal is usually preferred to prevent nausea.

• Diuretic Herbs: Supplements like dandelion root or green tea extract in high doses can contribute to dehydration and should be paused 24 hours before the procedure.
• Nephrotoxic Herbs: Any supplement with potential kidney toxicity (like certain traditional Chinese medicines or high-dose creatine) should be discussed with a doctor.

• Thyroid Function Tests: Iopamidol contains a large amount of iodine, which can interfere with thyroid uptake studies (radioactive iodine scans) for several weeks. If you need a thyroid scan, it should be done before the Iopamidol procedure or delayed by 4-6 weeks.
• Urine Tests: Iopamidol is excreted in the urine and can cause false-positive results for urine protein tests for up to 24-48 hours.
• Blood Tests: It may briefly interfere with certain spectrophotometric assays (tests that use light to measure chemicals in the blood).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for diabetes or high blood pressure.

There are very few absolute contraindications for Iopamidol, as it is often used in life-saving diagnostic situations. However, it should NEVER be used in the following case:

• Known Hypersensitivity to Iopamidol: If a patient has had a documented, severe anaphylactic reaction specifically to Iopamidol in the past, its use is absolutely contraindicated unless the diagnostic need outweighs the risk of death and the patient is pre-medicated in an intensive care setting.
• Intrathecal Administration of Specific Concentrations: High concentrations of Iopamidol (like 370 mgI/mL) are absolutely contraindicated for injection into the spinal fluid (myelography) as they are neurotoxic at that level.

These are conditions where the risk of using Iopamidol is higher, requiring a careful risk-benefit analysis by the physician:

• Severe Renal Impairment: If the kidneys are already failing, the risk of permanent damage from contrast is high.
• Dehydration: This must be corrected before the drug is administered.
• Multiple Myeloma: In patients with this blood cancer, the contrast agent can cause proteins in the blood to precipitate (clump) in the kidneys, leading to acute failure.
• Combined Renal and Hepatic Disease: When both major organ systems are impaired, the body’s ability to maintain balance is compromised.
• Active Hyperthyroidism: The risk of triggering a thyroid storm is a significant concern.
• Asthma: Patients with a history of asthma are statistically more likely to experience a bronchospasm reaction to the contrast.

Patients who are allergic to one type of iodinated contrast medium (like Iohexol or Iodixanol) are at a significantly higher risk of being allergic to Iopamidol. This is known as cross-sensitivity. However, because Iopamidol is non-ionic, patients who reacted to older ionic agents (like Diatrizoate) may sometimes tolerate Iopamidol better, though extreme caution is still required.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of asthma or kidney problems, before prescribing Iopamidol.

Iopamidol is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Risk-Benefit: Iopamidol should be used during pregnancy only if clearly needed. While the drug itself does not appear to be a major teratogen (cause of birth defects), the radiation from the X-ray or CT scan itself poses a risk to the developing fetus.
• Thyroid Monitoring: If a pregnant woman receives Iopamidol, the newborn's thyroid function should be monitored after birth, as the iodine can cross the placenta and affect the fetal thyroid gland.

Iopamidol is excreted into human breast milk in very small amounts (less than 0.01% of the dose). Studies have shown that the amount of iodine an infant would receive through breast milk is negligible.

• Current Guidelines: The American College of Radiology (ACR) states that it is safe to continue breastfeeding after receiving Iopamidol. While some older labels suggest waiting 24 hours, most modern clinical guidelines do not require a "pump and dump" period.

Iopamidol is widely used and approved for pediatric patients.

• Safety: It is generally safe, but infants (especially those under 1 year old) are at a higher risk for fluid and electrolyte imbalances due to the osmolality of the contrast.
• Thyroid Risk: There is a specific risk of transient hypothyroidism in neonates (especially premature infants). The FDA recommends monitoring thyroid levels in infants for several weeks following the procedure.

Elderly patients (65 and older) are at the highest risk for adverse effects from Iopamidol.

• Renal Clearance: Natural age-related decline in kidney function means the drug stays in the system longer.
• Comorbidities: Higher rates of heart disease and diabetes increase the risk of Contrast-Induced Nephropathy.
• Dosing: Physicians often use the lowest possible volume of contrast and ensure the patient is not dehydrated.

In patients with a Glomerular Filtration Rate (GFR) below 30-45 mL/min, the risk of Contrast-Induced Acute Kidney Injury (CI-AKI) is significant.

• Adjustments: There is no "dose adjustment" that makes the drug safer for the kidneys; rather, the total volume must be minimized.
• Dialysis: In patients already on chronic dialysis, Iopamidol can be given, but the timing of the next dialysis session may be adjusted to help clear the contrast, although this does not necessarily prevent kidney damage in those with some remaining function.

No specific dosage adjustments are required for patients with liver disease. However, if a patient has "hepatorenal syndrome" (where liver failure causes kidney failure), the renal precautions apply.

> Important: Special populations require individualized medical assessment to weigh the diagnostic benefits against the potential risks.

Iopamidol is a non-ionic, tri-iodinated, water-soluble, low-osmolar radiographic contrast medium. Its diagnostic efficacy is derived from the three iodine atoms attached to a benzene ring (the 5-acetamido-N,N'-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodoisophthalamide structure). These iodine atoms absorb X-ray photons via the photoelectric effect. Because the iodine concentration in the blood or organ becomes much higher than in the surrounding tissue, the X-ray beam is attenuated (blocked), creating a high-contrast image on the detector. As a non-ionic agent, Iopamidol does not dissociate in solution, which results in lower osmolality than older agents, significantly reducing the risk of osmotic-related side effects like pain or fluid shifts.

Iopamidol has no known therapeutic pharmacological effects. It does not bind to receptors or alter cellular function in its intended use. The "effect" is purely physical and immediate upon injection. The duration of the effect depends on the blood flow to the area (for angiography) or the rate of renal filtration (for urography). In a CT scan, the peak enhancement of organs like the liver occurs approximately 60-90 seconds after injection.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | < 5% |

| Half-life | ~2 hours (Normal renal function) |

| Tmax | Immediate (IV); 30-60 min (Urography) |

| Metabolism | Negligible (None) |

| Excretion | Renal >95%, Fecal <1% |

• Molecular Formula: C17H22I3N3O8
• Molecular Weight: 777.09 g/mol
• Solubility: Highly soluble in water.
• Structure: A substituted tri-iodinated isophthalic acid derivative. The non-ionic nature is achieved by the presence of multiple hydroxyl (-OH) groups, which make the molecule highly hydrophilic (water-loving) without needing to carry a charge.

Iopamidol belongs to the class of Non-ionic Iodinated Contrast Media. It is grouped with other similar agents such as Iohexol (Omnipaque) and Ioversol (Optiray). Within the broader therapeutic area, it is categorized as a Diagnostic Radiopharmaceutical/Contrast Agent.